TrialPloS one2016

A Proof of Concept, Phase II Randomized European Trial, on the Efficacy of ALF-5755, a Novel Extracellular Matrix-Targeted Antioxidant in Patients with Acute Liver Diseases.

Bertrand Nalpas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.